The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed K_Ca2 Activator and Na_V Blocker, is a Potent Novel Anticonvulsant

Abstract

Inhibitors of voltage-gated sodium channels (Na_v) have been used as anticonvulsants since the 1940s, while potassium channel activators have only been investigated more recently. We here describe the discovery of 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a thioanalog of riluzole, as a potent, novel anticonvulsant, which combines the two mechanisms. SKA-19 is a use-dependent Na_V channel blocker and an activator of small-conductance Ca²⁺-activated K⁺ channels. SKA-19 reduces action potential firing and increases medium afterhyperpolarization in CA1 pyramidal neurons in hippocampal slices. SKA-19 is orally bioavailable and shows activity in a broad range of rodent seizure models. SKA-19 protects against maximal electroshock-induced seizures in both rats (ED₅₀ 1.6 mg/kg i.p.; 2.3 mg/kg p.o.) and mice (ED₅₀ 4.3 mg/kg p.o.), and is also effective in the 6-Hz model in mice (ED₅₀ 12.2 mg/kg), Frings audiogenic seizure-susceptible mice (ED₅₀ 2.2 mg/kg), and the hippocampal kindled rat model of complex partial seizures (ED₅₀ 5.5 mg/kg). Toxicity tests for abnormal neurological status revealed a therapeutic index (TD₅₀/ED₅₀) of 6–9 following intraperitoneal and of 33 following oral administration. SKA-19 further reduced acute pain in the formalin pain model and raised allodynic threshold in a sciatic nerve ligation model. The anticonvulsant profile of SKA-19 is comparable to riluzole, which similarly affects Na_V and KCa2 channels, except that SKA-19 has a ~4-fold greater duration of action owing to more prolonged brain levels. Based on these findings we propose that compounds combining KCa2 channel-activating and Na_v channel-blocking activity exert broad-spectrum anticonvulsant and analgesic effects.

Electronic supplementary material

The online version of this article (doi:10.1007/s13311-014-0305-y) contains supplementary material, which is available to authorized users.

Introduction

Epilepsy, a complex neurological disorder estimated to affect over 50 million people worldwide, is characterized by recurrent spontaneous seizures due to neuronal hyperexcitability and hypersynchronous neuronal firing. Despite the availability of more than 20 antiepileptic drugs (AEDs) about 30 % of patients with epilepsy continue to experience seizures or suffer from unacceptable drug side effects [1, 2]. Therefore, there remains a substantial unmet need to identify AEDs with novel mechanisms of action that could be used either in monotherapy or integrated into combination regimens to obtain adequate seizure control for presently pharmacoresistant patients.

In general, there are currently three approaches for identifying new AEDs [1]. The first approach, which is intellectually most satisfying, is mechanism based: drugs are specifically developed to modify the function of molecular targets believed to be relevant to human epilepsy based on human mutations and/or genetic manipulations in rodents. An example is the ongoing search for potent and selective Kv7.2/7.3 (KCNQ2/3) activators like ICA-27243, ICA-105665 or other retibagine-related compounds [3–5]. These chemistry programs were initated based on the observation that loss-of function mutations in Kv7.2 (KCNQ2) have been associated with benign familial neonatal convulsions, a rare hereditary form of human epilepsy [6]. The second approach is to design follow-on compounds to existing AEDs with more favorable side effects or pharmacokinetic profiles, such as eslicarbazepine acetate as a third-generation follow-on drug to carbamazepine. The third approach, which has been pursued by the National Institutes of Health’s (NIH) Anticonvulsant Screening Program (ASP) since 1975, is empirical and uses rodent screening models. We here used a serendipitous combination of all 3 approaches to identify 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a thioanalog of riluzole, as a potent, novel anticonvulsant (Fig. 1).

Fig. 1.

Chemical structures of riluzole and 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19)

Riluzole, a compound first mentioned as a new chemical entity in a Russian-language publication on diazastyrenes dyes in 1963, was reported by scientists at Rhone Poulenc in 1985 to exhibit anticonvulsant effects in rodents and baboons [7]. Overall, the anticonvulsant spectrum seemed to be phenytoin-like and similar to other sodium channel-blocking AEDs [8]. Riluzole was subsequently extensively studied as a neuroprotective agent. In 1995, the US Food and Drugs Administration approved the use of riluzole, which is marketed under the trade name Rilutek (Sanofi-Aventis, Bridgewater, NJ, USA), for the treatment of amyotrophic lateral sclerosis and it still remains the only drug able to prolong survival in this fatal neurodegenerative condition [9]. Interestingly, despite being widely studied, riluzole had never been evaluated in the NIH ASP until our laboratory recently submitted it. Riluzole exhibits various pharmacological activities, the most prominent of which are inhibition of voltage-gated Na⁺ (Na_V) channels at concentrations of 1–50 μM and activation of small-conductance Ca²⁺-activated K⁺ channels with EC₅₀s of 10–20 μM [10, 11]. Riluzole has further been reported to inhibit delayed-rectifier K⁺ channels and to activate 2-pore K⁺ channels at 30–100 μM [12]. Riluzole’s relatively high potency as an activator of calcium-activated K⁺ channels (KCa) and its good pharmacokinetic properties rendered it an attractive template for the design of KCa channel modulators. Accordingly, our laboratory performed a structure–activity study of the riluzole pharmacophore and developed a series of compounds exemplified by SKA-31, which activates intermediate-conductance KCa3.1 and small-conductance KCa2 channels with EC₅₀ values of 250 nM or 2 μM, but was devoid of any significant Na_V channel-blocking activity [13]. As KCa2 channels are expressed in the hippocampus, amygdala, and cerebellum [14], where they participate in the regulation of neuronal after-hyperpolarization and excitability, and also serve as negative feedback regulators on the glutamate–N-methyl-d-aspartate pathway, KCa2 channel activators have been proposed for the treatment of central nervous system (CNS) disorders that are characterized by hyperexcitability such as epilepsy and ataxia [15]. As such, we submitted SKA-31 and several of its derivatives to the NIH’s ASP, where they were found to be effective in the maximal electroshock (MES) seizure model, the 6-Hz seizure model, and in the hippocampal kindled rat model. However, together with our relatively well characterized KCa2 channel activators we submitted several less well characterized riluzole derivatives and found SKA-19 to be a potent, orally active anticonvulsant. SKA-19 also reduced the acute pain response in the formalin pain model and raised the allodynic threshold in a sciatic nerve ligation model. Mechanism of action studies showed that SKA-19 suppresses Ca²⁺ oscillations in cultured hippocampal neurons induced by picrotoxin (PTX) and 4-aminopyridine (4-AP); reduces firing frequency and increases medium after-hyperpolarization currents in hippocampal slices; and inhibits Na_v channels, as well as activates KCa2 channels at low micromolar concentrations. Based on these findings we propose that compounds combining KCa2 channel-activating and state-dependent Na_v channel blocking activity exert broad-spectrum anticonvulsant and analgesic effects.

Materials and Methods

Drugs

SKA-19 (CAS 326-45-4) and riluzole (CAS 1744-22-5) were purchased from Oakwood Products (West Columbia, SC, USA) and recrystallized in our laboratory. ¹H and ¹³C nuclear magnetic resonance were used to confirm identity and purity.

Seizure Tests

SKA-19 and riluzole were tested under the auspices of the NIH’s ASP. Experiments were performed in male albino Carworth Farms No. 1 (CF-1) mice or Sprague–Dawley rats according to the established protocols of the ASP [16]. SKA-19 and riluzole were suspended in 0.5 % methylcellulose and administered in a volume of 0.01 ml/g body weight for mice and 0.04 ml/10 g body weight for rats.

MES Test

Animals received an electrical stimulus for 0.2 s (50 mA for mice and 150 mA for rats) at 60 Hz delivered via corneal electrodes. In the initial screens, mice were tested at 30 min and 4 h, and rats at time intervals between 0.25 and 4 h after test compound application. In the subsequent, quantitative tests at least 4 doses of SKA-19 (n = 8 animals per dose) were tested at the previously determined time of peak effect (TPE). Abolition of hindlimb tonic extension indicates the test compound’s ability to inhibit MES-induced seizure spread.

The MES testing (see Fig. 5) was performed at the Department of Neurology, University of California, Davis, and utilized male NIH Swiss mice (22–30 g) were obtained from the Animal Resource Program, National Cancer Institute (Bethesda, MD, USA). SKA-19 was solubilized in 5 % CremophorEL (Sigma-Aldrich, St. Louis, MO, USA) and 95 % saline to provide a clear, 5-mg/ml stock solution. Riluzole (5 mg/ml) was prepared in 10 % Captisol (Ligand Technology, La Jolla, CA, USA) and 90 % saline. Both stocks were diluted further with saline, and SKA-19 and riluzole were administered intraperitoneally (i.p.) as a clear solution in a volume of 10 ml/kg body weight. Animals were subjected to a 0.2-s, 60-Hz electrical stimulus through corneal electrodes (50 mA). Animals failing to show tonic hindlimb extension were scored as protected [17].

Fig. 5.

Comparison of seizure protection time course between riluzole and 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19). (a) Time course of seizure protection in the mouse maximal electroshock (MES) test following intraperitoneal (i.p.) administration of riluzole as a solution (n = 8 per time point). (b) Dose–response curves for seizure protection in MES test (□) and neurological impairment (■) following i.p. administration of increasing riluzole doses in mice (n = 8 per dose, 10-min time point). ED₅₀ 5.37 mg/kg [95 % confidence interval (CI) 5.17–5.57], TD₅₀ 15.77 mg/kg (95 % CI 11.94–20.83); protective index (PI) 2.9. (c) Time course of seizure protection in the mouse MES test following i.p. administration of SKA-19 as a solution (n = 6–8 per time point). (d) Dose–response curves for seizure protection in MES test (□) and neurological impairment (■) following i.p. administration of increasing SKA-19 doses in mice (n = 6–8 per dose, 10-min time point). ED₅₀ 4.93 mg/kg (95 % CI 4.15–5.86), TD₅₀ 16.08 mg/kg (95 % CI 13.06–19.02); PI 3.2

Subcutaneous Pentylenetetrazol (PTZ) Seizure Test

A dose of subcutaneous pentylenetetrazol (PTZ), which induces convulsions in 97 % of animals (CD97: 85 mg/kg mice or 56.4 mg/kg rats), was injected into a loose fold of skin at the neck. Animals were placed in isolation cages and observed for 30 min for the occurrence of clonic spasms persisting for at least 5 s. Test compound was administered i.p. or through oral dosing at various times before PTZ. Animals not exhibiting seizures were considered protected.

6-Hz Seizure Test

Seizures characterized by a minimal clonic phase followed by stereotyped automatistic behaviors were induced in mice by a low frequency (6 Hz), long-duration (3 s) stimulus delivered through corneal electrodes. At varying times (0.25, 0.5, 1, 2, and 4 h) after drug treatment, individual mice (4 at each time point) were challenged with a current of either 32 or 44 mA. Animals not displaying this behavior were considered protected.

Hippocampal Kindled Seizures

Bipolar electrodes were surgically implanted into the hippocampus of anesthetized male rats. One week after the surgery, rats were stimulated with suprathreshold trains of 200 μA for 10 s, 50 Hz, every 30 min for 6 h (12 stimulations per day) on alternate days until they were fully kindled. One week later the effect of a single i.p. dose of test compound was assessed on behavioral seizure score and afterdischarge duration. An initial group of kindled rats (n = 6–8) were tested at 15, 45, 75, 105, 135, 165, and 195 min after drug administration. Results were compared with the last control stimulus delivered 15 min prior to drug administration. Thus, each animal served as its own control. Scoring was performed as follows: stage 1 = mouth and facial clonus; stage 2 = stage 1 plus head nodding; stage 3 = stage 2 plus forelimb clonus; stage 4 = stage 3 plus rearing; stage 5 = stage 4 plus repeated rearing and falling.

Frings Audiogenic Seizure-susceptible Mice

Frings audiogenic seizure (AGS)-susceptible mice are genetically susceptible to sound-induced seizures [18]. A colony of AGS mice is maintained by the ASP at the University of Utah. Groups of 8 female mice (weighing 18–25 g) were treated i.p. with increasing doses of SKA-19. At the TPE in the MES test, mice were exposed to a sound stimulus of 110 decibels (11 KHz) delivered for 20 s. Mice were observed for the presence or absence of hindlimb tonic extension.

Intravenous PTZ Infusion Test

The intravenous (i.v.) PTZ test provides a measure of a test substance’s ability to raise or lower seizure threshold. Two doses of the test compound are employed in this test, the MES ED₅₀ and the TD₅₀, determined following i.p. quantification testing in mice. Accordingly, SKA-19 was tested at 5 and 30 mg/kg. Randomly selected male mice (n = 30) were injected i.p. 2 min apart with either the vehicle or the 2 test drug doses. At the previously determined TPE, 0.5 % heparinized PTZ solution was infused at a constant rate into a lateral tail vein. The time in seconds from the start of the infusion to the appearance of the “first twitch” and the onset of sustained clonus is recorded. The times to each endpoint are converted to mg/kg of pentylenetetrazol for each mouse. The mean (SE) for each of the 3 groups and the significance of the difference between the test groups and the control were calculated.

Test for Neurotoxicity

Abnormal neurological status in mice following the administration of SKA-19 and riluzole was evaluated with the rotorod test and the horizontal screen test as previously described [16]. For the experiment shown in Fig. 5, motor impairment was evaluated using a modification of the horizontal screen test as previously described [17]. Abnormal neurological status in rats was evaluated by the positional sense test, the muscle tone test, and the gait and stance test.

Statistical Analysis

ED₅₀s and TD₅₀ values were calculated by a FORTRAN probit analysis program, which provides the 95 % confidence intervals (CIs), the slope of the regression lines, and the SE of the slopes. For the experiments shown in Fig. 5 a similar log–probit analysis was performed to calculate ED₅₀, TD₅₀, and 95 % CIs with the Litchfield and Wilcoxon method (PHARM/PCS Version 4.2; Micro-Computer Specialists, Philadelphia, PA, USA).

Pain Assays

Formalin Pain Assay

SKA-19 was administered at a dose of 5 mg/kg to CF-1 male mice. At the previously determined time of peak anticonvulsant effect, 0.5 % formalin was injected subdermally into the plantar surface of the right hindfoot. For each animal the amount of time (s) spent licking the affected hind paw in a 2-min period was recorded at 5-min intervals and continued for 45 min through both the acute and inflammatory phase.

Partial Ligation of the Sciatic Nerve

Male rats were anesthetized with sodium pentobarbital, the sciatic nerve exposed, and approximately one-third to one-half of the nerve tied off. This procedure was performed on the right side (ipsilateral), while a sham surgery exposing, but not ligating, the nerve was performed on the left hindleg (contralateral). After 7 days of recovery animals were tested for the development of mechanical allodynia by placing them on a wire mesh (1/4”) platform. After 30–60 min of acclimatization a baseline mechanical sensitivity was determined by applying a series of calibrated Von Frey fibers perpendicularly to the plantar surface of each hindpaw. After a positive response (withdrawal of the foot) was noted a weaker fiber was applied. This was repeated until a 50 % threshold for withdrawal could be determined. The allodynic threshold was then redetermined after i.p. application of SKA-19 at 5 mg/kg.

Pharmacokinetics

All experiments were approved by the University of California, Davis, Institutional Animal Care and Use Committee. Nine–11-week-old male Sprague–Dawley rats were purchased from Charles River Laboratories (Wilmington, MA, USA). For i.v. application, SKA-19 was dissolved at 5 mg/ml in a mixture of 10 % CremophorEL (Sigma-Aldrich) and 90 % phosphate-buffered saline (Sigma-Aldrich, St. Louis, MO, USA), and then injected at 10 mg/kg into the tail vein. At various time points after the injection, ~100–200 μl blood was collected from a tail nick. Plasma was separated by centrifugation and stored at –80 °C. For i.p. application, SKA-19 was dissolved in Miglyol 812 neutral oil (caprylic/capric triglyceride; Neobee M5, Spectrum Chemicals, Gardena, CA, USA) at 2 mg/ml and injected at 10 and 30 mg/kg. After determining that SKA-19 plasma concentrations peaked 2 h after i.p. application, 2 groups of rats (n = 3 per group) received 10 mg/kg SKA-19 or riluzole, were subjected to cardiac puncture under deep isoflurane anesthesia 2 h later and then sacrificed before removing brain, heart, liver, spleen, and fat. Tissue samples were homogenized in 1 ml H₂O with a Brinkman Kinematica PT 1600E (KINEMATICA, INC., Bohemia, NY) homogenizer and the protein precipitated with 1 ml of acetonitrile. The samples were then centrifuged at 1620 g and supernatants concentrated to 1 ml. Plasma and homogenized tissue samples were purified using C₁₈ solid phase extraction cartridges. Eluted fractions corresponding to SKA-19 were dried under nitrogen and reconstituted in acetonitrile. Liquid chromatography/mass spectrometry (MS) analysis was performed with a Waters Acquity UPLC (Waters, Parsippany, NJ, USA) equipped with a Acquity UPLC BEH 1.7-μm RP-18 column interfaced to a TSQ Quantum Access Max MS (ThermoFisher Scientific, Waltham, MA, USA). The mobile phase consisted of acetonitrile and water, both containing 0.1 % formic acid. With a flow rate of 0.25 ml/min, the gradient was ramped from 95 % water to 95 % acetonitrile. Using electrospray ionization MS and selective reaction monitoring (capillary temperature 350 °C, capillary voltage 4000 V, collision energy –26 eV, positive ion mode), SKA-19 was quantified by its base peak of 182.9 m/z (C₇H₇N₂S₂⁺ fragment) and its concentration was calculated with a 9-point calibration curve from 50 nmol/l to 10 μmol/l. The percentage of plasma protein binding for SKA-19 was determined by ultrafiltration and was found to be 81.2 ± 1.1 % (n = 3). Very similar results [83 ± 1.1 % (n = 2)] were obtained by equilibrium dialysis.

Primary Cultures of Hippocampal Neurons

Brains were harvested from C57Bl/6 J mouse pups at postnatal day 0–1 in accordance with NIH guidelines and following approval by the University of California, Davis, Institutional Animal Care and Use Committee. Hippocampal neurons were dissociated from dissected hippocampi, plated onto a poly-l-lysine-coated clear-bottom, black wall, 96-well imaging plate (BD, Franklin Lakes, NJ, USA) at a density of 0.8 × 10⁵ cells/well, and maintained in Neurobasal (Life Technologies, Grand Island, NY) complete medium (Neurobasal medium supplemented with NS21, 0.5 mM l-glutamine, HEPES; Sigma-Aldrich) with 5 % fetal bovine serum (Life Technologies, Gibco^R). On day 2 in vitro, cytosine arabinoside (10 μM) was added to the culture to suppress the growth of astrocytes. Starting at 5 days in vitro (DIV), the medium was changed twice a week by replacing half the volume of culture medium in the well with serum-free Neurobasal complete medium.

Measurement of Synchronous Intracellular Ca²⁺ Oscillations

Hippocampal neurons 14–17 DIV were used for simultaneous measurements of intracellular Ca²⁺ transients in all wells of a 96-well plate as described previously [19]. After aspiration, the cells were incubated with 4 μM Fluo-4 in Locke’s buffer containing 0.5 mg/ml bovine serum albumin for 1 h at 37 °C. The plates were then transferred to the FLIPR (Molecular Devices, Sunnyvale, CA, USA) cell plate stage. After 4 min of baseline recordings, Ca²⁺ signals were then recorded for 10 min in the presence or absence of SKA-19 followed by addition of the Ca²⁺ enhancing agents 4-AP or PTX, and the intracellular Ca²⁺ concentration ([Ca²⁺]_i) was monitored for an additional 30 min. Ca²⁺-enhancing agents triggered an immediate rise in [Ca^2+]_i that was quantified by determining the area under the curve of the Fluo-4 arbitrary fluorescence units for a duration of 5 min following agent addition.

Slice Recordings

Brain slice preparation was approved by the University of California, Irvine, Institutional Animal Care and Use Committee. Male C57BL/6 J mice (postnatal day 23) were anesthetized with halothane, decapitated, and brains transferred to an ice-cold, sucrose artificial cerebral spinal fluid (ACSF; Sigma-Aldrich). Hippocampal slices (300 μm) were prepared using a Leica VT1200S vibrating blade microtome (Leica Microsystems Inc., Buffalo Grove, IL). Slices were incubated at 33 °C in oxygenated (95 % O₂, 5 % CO₂) standard ACSF containing the following (mM) for at least 1 h before recordings: 126 NaCl, 2.5 KCl, 1.25 NaHPO₄, 1.2 MgSO₄, 10 glucose, 1.2 CaCl₂, and 26 NaHCO₃ . Slices were submerged and continuously perfused at 2 ml/min with oxygenated ACSF at 33 °C during the current–clamp experiments. Voltage–clamp experiments were performed in the same ACSF but with 1 mM tetraethylammonium chloride (Sigma-Aldrich) and 0.5 μM tetrodotoxin (Sigma-Aldrich) added. Pyramidal CA1 neurons were visualized and identified with an upright microscope (Zeiss Axioskop Plus; Zeiss Jena, Germany) with infrared differential interference contrast optics. Recording pipettes (2–5 MΩ) were filled with intracellular solution containing (in mM): 126 K-gluconate; 4 KCl; 10 HEPES; 2 Mg–adenosine triphosphate; 0.3 Tris–guanosine triphosphate; 10 phosphocreatine, pH 7.20, 270–290 mOsm. In the current–clamp mode, depolarizing current pulses were applied from a membrane potential of −65 mV to evoke tonic firing activity. In the voltage–clamp mode, neurons were held at –55 mV and KCa currents elicited by 50-ms voltage steps to 10 mV, applied every 10 s. SKA-19 or NS309 were perfused for 10 min into the bath to allow for equilibrium. Recordings were performed in the whole-cell mode using a MultiClamp 700B amplifier (Molecular Devices), digitized at 4 kHz and sampled at 20 kHz with a Digidata 1322A digitizer (Molecular Devices). Data were acquired and analyzed with pClamp 10.2 software (Molecular Devices).

Voltage–Clamp Experiments

All experiments were conducted at room temperature (22–24 °C) with an EPC-10 amplifier and Pulse software (HEKA, Lambrecht/Pfalz, Germany) in the whole-cell mode of the patch–clamp technique. Human embryonic kidney (HEK)-293 cell lines stably expressing hNa_V1.1, hNa_V1.5, hNa_V1.7 channels (generously provided by Dr. Christopher Lossin, University of California Davis), hNa_V1.4 (Frank Lehmann-Horn, University of Ulm), or hK_V2.1 channels (James Trimmer, University of California Davis) were bathed in extracellular solution containing (in mM): 160 NaCl; 4.5 KCl; 1 MgCl₂; 2 CaCl₂; 10 HEPES [pH was adjusted to 7.4 using NaOH (310 mOsm)]. Pipettes were filled with intracellular solution containing (in mM): 145 KF; 2 MgCl₂; 10 ethylene glycol tetraacetic acid; 10 HEPES (pH adjusted to 7.2 with KOH; 300 mOsm). Neuroblastoma N1E-115 cells (ATCC, Manassa, VA, USA) expressing Na_V1.2 were patched with a CsF internal solution consisting of (in mM): 10 NaF; 110 CsF; 20 CsCl; 2 ethylene glycol tetraacetic acid; 10 HEPES (CsOH to pH 7.35; 300 mOsm). All pipette tip resistances were 2–4 MΩ. Series resistances of 3–10 MΩ were compensated 40–80 %. All cells were voltage-clamped to a holding potential of –90 mV unless otherwise specified. The sampling frequency was 5 kHz. Na⁺ currents were elicited by 30-ms pulse to 0 mV from –90 mV applied every 10 s. K_V2.1 currents were elicited by 200-ms voltage steps from –90 to 40 mV applied every 10 s.

HEK-293 or COS-7 cells stably expressing hKCa2.1, rKCa2.2, and hKCa2.3 have been described previously [13]. Cells were held at –80 mV and KCa currents elicited by dialysis with a K⁺ aspartate based internal containing 250 nM free Ca²⁺ (pH 7.2, 290 mOsm, pipette resistance 1.5 MΩ). To reduce currents from native chloride channels, Na⁺ aspartate Ringer was used as an external solution. KCa2 currents were recorded with 200-ms voltage ramps from –120 to +40 mV applied every 10 s, and the fold increase of slope conductance at –80 mV by drug was taken as a measure of channel activation. Data analysis, fitting, and plotting were performed with IGOR-Pro (Wavemetrics, Lake Oswego, OR, USA) and Origin 9.0 (OriginLab, Northampton, MA, USA).

Results

SKA-19 is Active in the MES Seizure Test

SKA-19 was evaluated for antiseizure activity in the initial qualitative screens of the ASP, which are used for routine identification of potential novel anticonvulsants. These so-called “identification” tests evaluate a compound at increasing doses in the MES and the subcutaneous PTZ tests combined with an initial assessment of toxicity in the rotorod test. SKA-19 fully protected mice in the MES model following i.p. administration at 10, 30, and 100 mg/kg, and exhibited partial protection at 3 mg/kg. However, it did not provide any protection in the PTZ test at 30 and 100 mg/kg, while one animal treated with 300 mg/kg died in the PTZ test without exhibiting a seizure. Preliminary toxicity testing for neurological deficits revealed no impairment of motor performance in the rotorod test at 0.5 and 4 h after doses of 3, 10, and 30 mg/kg, but showed inability to clasp the rotorod at 100 mg/kg, and sedation or death at 300 mg/kg. Following oral administration at 30 mg/kg, SKA-19 also fully protected rats in the MES test at all time points (0.25, 0.5, 1, 2, and 4 h) without inducing motor impairment (n = 4).

As this initial screen showed activity in the MES test in 2 species and an encouraging difference between efficacy and neurotoxicity, we next evaluated SKA-19 quantitatively. When tested for seizure protection in the MES test following i.p. administration at 4 doses (n = 8 per dose) SKA-19 was found to have an ED₅₀ of 4.8 mg/kg [95 % confidence interval (CI) 4.05–5.37] in mice and an ED₅₀ of 1.6 mg/kg (95 % CI 1.24–1.94) in rats (Fig. 2). Simultaneously performed testing for motor impairment revealed a TD₅₀ for affecting the ability of mice to stay on the rotorod of 29.8 mg/kg (95 % CI 25.35–35.98; 6 doses, n = 8 per dose). At 100 mg/kg 2/8 mice died. The neurological status of rats was determined by their ability to perform normally in 3 simple neurological tests; SKA-19 impaired the neurological function with a TD₅₀ of 14.33 mg/kg (95 % CI 10.72–17.9; 5 doses, n = 8 per dose). Taken together, these tests rendered a therapeutic (TD₅₀/ED₅₀) or protective index (PI) of 6.2 for mice and of 8.9 for rats following i.p. application. As is generally the case, the PI was found to be considerably higher (~33) following oral application in rats (Fig. 2) which rendered an ED₅₀ in the MES test of 2.33 mg/kg (95 % CI 1.30–3.39; 4 doses, n = 8 per dose) and a TD₅₀ of 77.38 mg/kg (95 % CI 62.55–91.01). No deaths occurred in rats at higher doses. Similar findings were made following oral application in mice (data not shown; MES ED₅₀ 4.31 mg/kg, TD₅₀ 78.63 mg/kg).

Fig. 2.

2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19) protects mice and rats in the maximal electroshock (MES)-induced seizure model. (a) Dose–response curves for seizure protection in the MES test (□) and neurological impairment (■) following intraperitoneal (i.p.) administration in mice (n = 8 per dose, 2-h time point). ED₅₀ 4.8 mg/kg [95 % confidence interval (CI) 4.05–5.37], TD₅₀ 29.8 mg/kg (95 % CI 25.35–35.98); protective index (PI) 6.2. (b) Dose–response curves for i.p. administration in rats (n = 8 per dose, 1-h time point). ED₅₀ 1.6 mg/kg (95 % CI 1.24–1.94), TD₅₀ of 14.33 mg/kg (95 % CI 10.72–17.9); PI 8.9. (c) Dose–response curves for oral administration in rats (n = 8 per dose, 4-h time point). ED₅₀ 2.33 mg/kg (95 % CI 1.3–3.39), TD₅₀ 77.38 mg/kg (95 % CI 62.55–91.01); PI 33.2

Interestingly, when we subsequently submitted riluzole to the ASP, this clinically used drug was found to exhibit a surprisingly high toxicity when given i.p.. In the initial screen, riluzole already affected rotorod performance and righting reflexes in 8/8 mice at 30 mg/kg and killed 8/8 mice at 100 mg/kg following i.p. application. In rats, a dose of 30 mg/kg i.p. completely protected animals from MES-induced seizures but also killed one animal and induced neurological deficits in 4/4 animals. Subsequent quantitative evaluation of riluzole in the mouse MES test rendered an ED₅₀ of 4.07 mg/kg (95 % CI 3.28–4.85; 6 doses, n = 8 per dose) and a TD₅₀ of 17.27 mg/kg (95 % CI 15.58–19.14; 6 doses, n = 8). Riluzole was further looked at after oral application in rats, where it was found to have an ED₅₀ of 2.64 mg/kg (95 % CI 1.81–3.75; 4 doses, n = 8 per dose) and a TD₅₀ of 21.44 mg/kg (95 % CI 14.59–27.85). Riluzole was also much better tolerated in mice after oral application (TD₅₀ 55.26 mg/kg; 95 % CI 46.35–65.98). Based on this much better oral tolerability and the MES experiments (shown in Fig. 5) showing no significant difference in the toxicity of SKA-19 and riluzole when administered as solutions, we believe that there is no substantial difference in the relative toxicity of the 2 compounds and that the differences observed in the initial screen were probably caused by quicker absorption of riluzole out of the methylcellulose suspension used by the ASP. In keeping with this notion, riluzole typically reached its maximal effect more quickly (0.25 or 0.5 h) than SKA-19. Like SKA-19, riluzole showed no significant activity in the PTZ test.

SKA-19 is Active in the 6-Hz Seizure Test, Hippocampal Kindled Rats, and the Frings AGS Susceptible Mouse Model

SKA-19 was also examined in an alternative electroshock test, the 6-Hz seizure test in mice. The 6-Hz test is a limbic seizure model induced by a low frequency, long-duration stimulus delivered by a corneal electrode [16]. It produces an initial stun followed by vibrissae chombing, forelimb clonus, and a Straub tail. In an initial screen SKA-19 exhibited full protection (4/4 animals) 2 h after i.p. administration of 10 mg/kg and partial protection at all other tested time points. Subsequent quantitative testing of multiple doses at the 2 h time point (Fig. 3a) gave an ED₅₀ of 12.19 mg/kg (95 % CI 8.2–17.45; n = 8 per dose). A second set of 6-Hz experiments was performed with a higher current intensity of 44 mA at which the 6-Hz test becomes more discriminatory and has been suggested as a model for therapy-resistant seizures [20]. At this higher current intensity SKA-19 was found to exhibit an ED₅₀ of 28.15 mg/kg (95 % CI 18.14–46.78; n = 8 per dose). However, it should be noted when judging the 6-Hz test that SKA-19 was tested at 5, 10, 20, 40, and 60 mg/kg, and that the 40 and 60 mg/kg doses are above the TD₅₀ (29.73 mg/kg) for affecting mouse rotorod performance. Orally administered riluzole exhibited similar efficacy in the 6-Hz test, but reached its peak effect earlier than SKA-19 (ED₅₀ 10.1 mg/kg with a current intensity of 32 mA, and 11.54 mg/kg with a current intensity of 44 mA at the 0.5-h and 1-h time points, respectively).

Fig. 3.

2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19) shows efficacy in multiple seizure models. (a) 6-Hz seizure test in mice: ED₅₀ 12.19 mg/kg [95 % confidence interval (CI) 8.2–17.45, n = 8 per dose]. See Fig. 2 for mouse TD₅₀ 2 h after intraperitoneal (i.p.) application. (b) Hippocampal kindled rats: ED₅₀ 5.47 mg/kg (95 % CI 2.92–8.92, n = 8 per dose). (c) Frings audiogenic seizure (AGS)-susceptible mouse model: ED₅₀ 2.15 mg/kg (95 % CI 1.52–2.65, n = 8 per dose). In all cases, testing was performed 2 h after i.p. application of SKA-19

SKA-19 was next evaluated in hippocampal kindled rats, a model that can predict efficacy of an AED for treating complex partial seizures and preventing seizure spread from a focus [1, 16]. In a preliminary experiment with 2 fully kindled rats SKA-19 at 30 mg/kg i.p. reduced the predrug seizure score from 4–5 to 0 and completely suppressed the afterdischarge duration. As shown in Fig. 3b, a quantitative test of increasing doses in kindled rats determined an ED₅₀ of 5.47 mg/kg (95 % CI 2.92–8.92; n = 8 per dose) with no evidence of toxicity at the highest dose (15 mg/kg) in these “seizure experienced animals”, despite the fact that this dose was similar to the previously determined TD₅₀ in normal, not kindled, rats (see Fig. 2b). In lamotrigine-resistant amygdala-kindled rats, SKA-19 only exhibited partial protection with 2/8 rats protected at 6 mg/kg and 3/7 fully kindled rats protected at 50 mg/kg.

SKA-19 was further evaluated in the Frings AGS-susceptible mouse model [18]. Frings AGS-susceptible mice exhibit sound-induced seizures, which manifest as wild running, loss of righting reflex, tonic flexion, and tonic extension in response to high-intensity sound stimulation such as a 20-s 110 decibels sound. While the model typically does not differentiate well between different anticonvulsants and is not useful for identifying compounds effective in difficult-to-treat partial seizures [21], its utility rests in its usefulness at predicting potential efficacy against hereditary epilepsy. As shown in Fig. 3c, SKA-19 protected Frings AGS-susceptible mice from sound induced seizures with an ED₅₀ of 2.15 mg/kg (95 % CI 1.52–2.65; n = 8 per dose).

SKA-19 Does Not Affect Seizure Threshold in the i.v. PTZ Test

As some anticonvulsants can paradoxically reduce seizure threshold and thus exhibit proconvulsant activity under certain circumstances, SKA-19 was evaluated in the i.v. PTZ test, which determines whether a compound reduces or increases the time to the first twitch or to clonus during a continuous i.v. infusion of PTZ. Vehicle or SKA-19 at 5 and 30 mg/kg, doses corresponding to the mouse MES ED₅₀ and the mouse TD₅₀ (Fig. 2), were administered i.p. to mice (n = 10 per group). The lower dose did not change the time to the first twitch or clonus, while the higher dose increased both slightly [PTZ to first twitch: vehicle 28.0 ± 0.96 mg/kg, SKA-19 31.6 ± 1.0 mg/kg (p = 0.008); PTZ dose to first clonus: vehicle 30.6 ± 1.19 mg/kg, SKA-19 37.2 ± 1.25 mg/kg (p = 0.000)]. This slight elevation in threshold at 30 m/kg is in keeping with SKA-19 having antiseizure activity and demonstrates that SKA-19 is not proconvulsant.

Pharmacokinetics of SKA-19

The anticonvulsant testing at the ASP had shown that SKA-19 must have a relatively good bioavailability as it was effective following both oral and i.p. application as a suspension in 0.5 % methylcellulose. Activity typically peaked between 1 and 2 h and lasted 4 h, sometimes even longer as in the case of the sedation and neurological impairment, which were observable for up to 24 h following administration of 200 mg/kg SKA-19 in the toxicity studies. This prolonged effect suggested a half-life somewhere between 1 and 3 h. In order to determine the pharmacokinetic properties of SKA-19 we established an ultra performance liquid chromatography/MS assay based on a high-performance liquid chromatography/MS assay we had previously published for the benzothiazole SKA-31 [13], and determined total SKA-19 plasma concentrations in rats following i.v., i.p,. and oral application as solution. Following i.v. administration at 10 mg/kg (n = 3), SKA-19 plasma concentrations fell biexponentially, reflecting a 2-compartment model with very rapid distribution from blood into tissue followed by elimination with a half-life of 2.2 h (Fig. 4a). Following oral administration of a solution of 10 mg/kg, SKA-19 plasma concentrations stayed around 1 μM for 5 h and then fell to 0.4 μM at 8 h (Fig. 4b). Gavage of SKA-19 as a suspension in methylcellulose as used by the ASP resulted in a very similar plasma concentrations (Fig. 4b). The plasma peak was slightly delayed and the peak concentration slightly higher (1.6 ± 0.6 μM); however, the overall exposure level was not significantly different. Oral availability was found to be roughly 30 % in both vehicles.

Fig. 4.

Pharmacokinetics of 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19). (a) Total SKA-19 plasma concentrations (mean ± SD) following intravenous administration of 10 mg/kg in CremophorEL (Sigma-Aldrich, St. Louis, MO, USA)/phosphate-buffered saline to male Sprague–Dawley rats (n = 3). The inset shows the same data on a log scale. The data were best fitted as biexponential decay and with a quick distribution into tissue followed by elimination (t_1/2 = 2.16 ± 0.023 h). (b) SKA-19 plasma concentrations following oral gavage application at 10 mg/kg in solution (n = 3) or as a methylcellulose suspension (n = 3). (c) Plasma concentrations following intraperitoneal (i.p.) application at 10 and 30 mg/kg (n = 3). (d) Tissue concentrations 2 h after i.p. administration of SKA-19 and riluzole at 10 mg/kg (n = 3)

We further injected SKA-19 i.p. at doses of 10 and 30 mg/kg (Fig. 4c). In keeping with the high total plasma concentrations measured at 2 h (11.96 ± 2.21 μM; n = 3) and 4 h (13.09 ± 2.67 μM), rats receiving 30 mg/kg showed prolonged sedation but recovered without weight loss at 24 h. Tissue concentration determinations performed 2 h after i.p. application of 10 mg/kg revealed that SKA-19 is very effective at penetrating into tissues such as brain, heart, spleen, and liver (Fig. 4c). A direct comparison with the same dose of riluzole (10 mg/kg i.p.), which resulted in very similar plasma concentrations at 2 h (4.6 ± 1.3 μM for SKA-19 and 4.1 ± 0.2 μM for riluzole), showed that SKA-19 reached roughly 3-fold higher brain than plasma concentrations, while riluzole exhibited a brain plasma ratio of 1:1 in our hands (Fig. 4c). We further determined the plasma protein binding of SKA-19 and found 82 % bound with rat plasma.

Direct Comparison of Riluzole and SKA-19 in MES Seizure Test

In order to directly compare SKA-19 and riluzole we next performed a set of MES experiments in mice. Both SKA-19 and riluzole were administered i.p. as solutions in a volume of 10 ml/kg to assure quick and efficient absorption. Protection from seizures induced by corneal electrodes was seen as early as 5 min after application of both compounds (Fig. 5). However, riluzole only provided a relatively short-lived protection and even 10 mg/kg was not protective for longer than 45 min (Fig. 5a). In contrast, SKA-19 provided full protection for 2.5 h at the 10 mg/kg dose and significant seizure protection at 5 and 6 mg/kg for at least 90 min (Fig. 5c). Quantitative testing at the 10 min time point rendered an ED₅₀ of 4.93 mg/kg (95 % CI 4.15–5.86; n = 6–8 per dose) and a TD₅₀ of 16.08 (95 % CI 13.06–19.02) for SKA-19, and very similar ED₅₀ and TD₅₀ values for riluzole (Fig. 5b, d).

The PI (TD₅₀/ED₅₀) for SKA-19 in these experiments was lower (PI 3.2) than with the suspension preparation used by the ASP but the ED₅₀ was identical to the mouse ED₅₀ determined in the MES test by the ASP at 2 h, suggesting that the severity of the neurological impairment induced by SKA-19 depends, in part, on how quickly brain concentrations rise. The brain is a well perfused organ and following i.p. administration of SKA-19 in a high volume, brain concentrations are likely to rise much more quickly than after i.p. administration of a suspension. In keeping with this interpretation, SKA-19 displayed the lowest toxicity following oral application. In this case, the PI was found to be 33 (Fig. 2c), probably because brain concentrations rose more slowly in parallel with the slower rise in plasma concentrations observed after oral dosing (Fig. 4b).

SKA-19 Shows Efficacy in Pain Models

Intraplantar injection of a dilute formalin solution (0.5 %) into the hindpaw induces a biphasic pain response in mice. Immediately following the injection the mouse intensely lifts, licks, and flicks the paw for approximately 5–10 min. This first phase (phase I) is thought to result from a direct activation of primary afferent neurons and has recently been shown to be largely caused by direct stimulation of transient receptor potential cation channel, member A1 (TRPA1) [22]. After a brief latent period where there is little behavioral activity, a more prolonged second phase (phase II) of about 30–60 min of activity then ensues, which is characterized by sensitization of CNS neurons in the dorsal horn, continuing afferent input, and inflammation. SKA-19 administration at 5 mg/kg 2 h prior to formalin injection significantly decreased nociceptive behavior measured as the amount of time animals spent licking the affected hindpaw in a 2-min period recorded at 5-min intervals in phase I and the early phase II (Fig. 6a). Quantification by determining the area under curve showed a 54.5 % reduction of the total paw licking in phase I (n = 8 per group; p < 0.05) and a 31.3 % reduction of paw licking in phase II (p < 0.05), which the individual time points showing significant reductions up to 20 min.

Fig. 6.

2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19) is effective in pain models. (a) SKA-19 (5 mg/kg administered 2 h prior to formalin injection) significantly decreased the time mice spent licking the affected hindpaw in a 2-min period recorded at 5-min intervals in the formalin pain test (n = 8 per group). (b) Threshold for foot withdrawal in response to a series of calibrated Von Frey fibers in rats 7 days (n = 8) after recovery from nerve ligation surgery following administration of SKA-19 (5 m/kg)

SKA-19 was further evaluated for its ability to raise allodynic threshold in a Von Frey test following partial sciatic nerve ligation in rats (Fig. 6b). The threshold for foot withdrawal in response to a series of calibrated Von Frey fibers was determined in rats 7 days after recovery from nerve ligation surgery (n = 8). Subsequent SKA-19 administration at 5 mg/kg significantly increased the withdrawal threshold at the 2-h time point.

SKA-19 Reduces 4-AP and PTX-Induced Ca²⁺ Oscillations in Hippocampal Neurons

In order to identify the mechanism of action of SKA-19, we started by testing its effect on neuronal Ca²⁺ oscillations. Cultured hippocampal neurons display spontaneous synchronous Ca²⁺ oscillations the frequency and amplitude of which can be monitored in real-time using FLIPR Tetra [19]. While SKA-19 concentrations of ≤1 did not significantly inhibit spontaneous Ca²⁺ oscillations, SKA-19 concentrations of 3 μM or more completely eliminated spontaneous Ca²⁺ oscillations (Fig. 7a), suggesting that SKA-19 affects neuronal excitability. We next investigated the effect of SKA-19 on Ca²⁺ oscillations induced by the proconvulsant agents 4-AP and picrotoxin (PTX). While the K⁺ channel blocker 4-AP produced an immediate elevation of neuronal intracellular Ca²⁺ later followed by a drastically increased Ca²⁺ oscillation frequency with lower amplitude (Fig. 7b), the gamma-aminobutyric acid (GABA) receptor A (GABA_A) blocker PTX caused a sharper and more transient rise in intracellular Ca²⁺, which was followed by a decrease in the frequency but a rise in the amplitude of Ca²⁺ oscillations (Fig. 7c). SKA-19 potently suppressed both the initial rise and the oscillations induced by both agents, suggesting that it significantly affects neuronal activities driving the Ca²⁺ oscillations induced by 4-AP and PTX in these neuronal networks.

Fig. 7.

Increasing concentrations of 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19) inhibit (a) spontaneous, and (b) 4-aminopyridine (4-AP)- and (c) picrotoxin-induced Ca²⁺ oscillations in cultured 14 days in vitro (DIV) hippocampal neurons. (a) SKA-19 concentrations of 1 μM or less have no effect on spontaneous Ca²⁺ oscillations. The arrow indicates addition of SKA-19. (b) 4-AP (1 μM, arrow indicates addition) produces an immediate but transient elevation in neuronal intracellular Ca²⁺ followed by increased Ca²⁺ oscillation frequency with lower amplitude. The initial rise and the oscillations are inhibited by SKA-19. SKA-19 was added 10 min before 4-AP. (c) Picrotoxin (PTX; 10 μM, arrow indicates addition) induces higher amplitude Ca²⁺ oscillations, which are inhibited by SKA-19 (added 10 min before PTX). VEH = vehicle

SKA-19 Reduces AP Firing in CA1 Pyramidal Neurons by Inhibiting Na_V Channels and Activating KCa2 Channels

As SKA-19 is a potent anticonvulsant in multiple seizure models and suppresses neuronal Ca²⁺ oscillations, we next tested its effect on firing of CA1 pyramidal neurons in mouse hippocampal slices. Under normal conditions CA1 neurons started firing action potentials (APs) following injection of 30-pA current and subsequently fired APs with increasing frequency at higher current injections. Following a 1-s 150-pA current injection to elicit a series of APs, application of 1 μM SKA-19 slowed down AP firing, while 25 μM completely suppressed it (Fig. 8a). The intermediate concentration of 10 μM of SKA-19 reduced the number of spikes at all injected current levels by roughly 50 % (Fig. 8b). A close inspection of individual APs revealed that exposure to 10 μM SKA-19 was associated with an increase in after-hyperpolarization amplitude, suggesting that the effect of SKA-19 is at least partly due to the activation of KCa2 (=SK) channels. To provide support for this conclusion we compared the effect of SKA-19 with the effect of the more specific KCa2 channel activator NS309 (data not shown). At 10 μM, a concentration at which it had previously been shown to exert saturating effects on the medium afterhyperpolarization (mAHP) in CA1 pyramidal neurons in rat hippocampal slices [23], NS309 reduced AP firing frequency following 1-s current injections (150 pA) from a holding potential of –65 mV; however, unlike SKA-19 under the same conditions, it did not terminate firing during the ongoing current train, suggesting that SKA-19 has additional effects on other channels than KCa2 channels. To confirm that SKA-19 reduces neuronal firing at least partly by enhancing KCa2 channel activity, we directly measured the mAHP current in the presence or absence of SKA-19 in voltage–clamp experiments. SKA-19 induced a modest but significant increase in the mAHP amplitude compared with control (Fig. 8c). We next tested SKA-19 on KCa2 channels stably expressed in HEK-293 cells. In whole-cell patch–clamp recordings SKA-19 potentiated KCa2.2 (SK2) and KCa2.3 (SK3) currents elicited by 250 nM of free intracellular Ca²⁺ with EC₅₀ values of 14 and 15 μM (Fig. 8d, e; Table 1). Similar to other positive KCa channel gating modulators like SKA-31 and NS309 [13], SKA-19 maximally increased KCa2 currents 30-fold at this intracellular Ca²⁺ concentration. Interestingly, SKA-19 displayed selectivity for KCa2.2 and KCa2.3 over KCa2.1, and only showed very weak effects on KCa2.1 currents at concentrations of 100 and 200 μM (Fig. 8e).

Fig. 8.

2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19) reduces action potential (AP) firing of hippocampal pyramidal neurons by activating KCa2 channels and inhibiting voltage-gated Na⁺ channels (Na_V) channels. (a) Overlay of representative AP traces recorded before (black) and after (red) perfusion of 1 μM SKA-19 (left) or 25 μM SKA-19 (right). Cells were held at –65 mV and a train of APs evoked by a 1-s 150-pA current injection. (b) Overlay of AP traces recorded in the absence and presence of 10 μM SKA-19 (left), and plot of the number of APs elicited in the presence (red) and absence of SKA-19 in response to stimulating current injections of increasing amplitude (right). Data points represent means and SDs for 3 independent neurons. (c) SKA-19 enhances the medium afterhyperpolarization (AHP). SKA-19 at a concentration of 10 μM increases the amplitude of the current underlying the medium AHP. Shown on a compressed (left) and expanded time scale (middle). Bar graph of normalized mI_AHP current amplitude (right). Shown are means and SDs for 3 neurons. (d) SKA-19 activates rKCa2.2 and hKCa2.3 stably expressed in human embryonic kidney-293 cells. (e) Concentration–response curve for the activation of KCa2.1, KCa2.2, and KCa2.3 recorded in the presence of 250 nM of free intracellular Ca²⁺. See Table 1 for EC₅₀ values. (f) SKA-19 is a state- and use-dependent inhibitor of Nav1.2 currents in N1E-115 neuroblastoma cells. Sample Na_V1.2 current traces blocked by 1 μM and 10 μM SKA-19 (left). State-dependence (middle): IC₅₀ at –70 mV holding potential is 0.86 ± 0.70 μM; IC₅₀ at –90 mV holding potential is 7.90 ± 0.01 μM; IC₅₀ at –120 mV holding potential is 9.50 ± 1.72 μM. Use-dependence (right): IC₅₀ at 0.1 Hz is 7.90 ± 0.01 μM; IC₅₀ at 20 Hz is 0.52 ± 0.23 μM. Data points represent means plus SDs extracted from recordings from at least 3 independent cells

Table 1.

Selectivity of 2-amino-6-trifluoromethylthio-benzothiazole

Channels	EC50 or IC50 (µM)	n
KCa2.1	> 100	5
KCa2.2	14 ± 5	12
KCa2.3	15 ± 5	14
NaV1.1	6.9 ± 4.9	5
NaV1.2	7.9 ± 0.02	3
NaV1.4	2.2 ± 1.1	6
NaV1.5	4.5 ± 2.7	7
NaV1.7	5.8 ± 2.6	3
KV2.1	22.3 ± 5.6	3

n number of cells used per experiment

Based on its structural similarity to riluzole, its sedating properties at higher concentrations and its pronounced effects on neuronal firing (Fig. 8a, b), we further suspected that SKA-19 would also block Na_V channels and therefore investigated its blocking properties on several sodium channel isoforms. SKA-19 inhibited Na_V1.1 and Na_V1.2, 2 of the major neuronal sodium channels, with IC₅₀ values of approximately 7.90 ± 0.01 μM (Fig. 8f; Table 1) when cells were held at –90 mV and pulsed with a frequency of 0.1 Hz. Changing the holding potential or the pulse frequency to 20 Hz revealed that inhibition by SKA-19 was highly state- and use-dependent as both manipulations significantly affected the IC₅₀ for Na_V1.2 by lowering it to 860 or 520 nM, respectively (Fig. 8f). As expected, SKA-19 did not exhibit any selectivity among sodium channel isoforms and also blocked Na_V1.4, Na_V1.5, and Na_V1.7 in the low micromolar range (Table 1). Taken together, SKA-19 therefore seems to be a “dirty” ion channel modulator that exerts its anticonvulsant and analgesic effects through a combination of KCa2 channel-activating and Na_v channel-blocking activity.

Discussion

Epilepsy and neuropathic pain are characterized by abnormal excessive or ectopic neuronal excitability. Drugs currently used in the clinic to treat epilepsy include inhibitors of voltage-gated Na⁺ and Ca²⁺ channels, activators of voltage-gated K⁺ channels, and modulators of GABAergic inhibitory and glutamatergic excitatory neurotransmission [24], while the anticonvulsants gabapentin, pregabalin, carbamazepine, and lamotrigine are also used for the treatment of neuropathic pain [25]. We here describe the discovery of SKA-19, a thioanalog of riluzole, which is orally available, brain penetrant, and displays activity in several rodent seizure models. SKA-19 has a dual mechanism of action and is both a use- and state-dependent Na_V channel blocker and an activator of small-conductance Ca²⁺-activated KCa2 K⁺ channels. Through this dual mechanism SKA-19 reduces neuronal excitability in 2 ways: it decreases firing frequency and increases medium after-hyperpolarization. Both targets, Na_V and KCa2 channels, are expressed at high levels in the brain, including in regions relevant to seizure disorders, such as cortex, hippocampus, and thalamus. Na_V1.1 and Na_V1.2 may play an important role in the control of neuronal excitability and epileptiform activity [26]. More than 100 different mutations in the genes encoding Na_V1.1 and Na_V1.2, SCNA1 and SCNA2, have been identified in patients with genetic epilepsy with febrile seizures. Missense mutations in SCN2A have further been found in patients with benign familial neonatal convulsions [27], while SCNA1 mutations also seem to cause 2 other severe epilepsy syndromes of early life: Dravet syndrome and intractable childhood epilepsy with generalized tonic–clonic seizure [26]. Another strong argument for the importance of Na_V channels in seizures is, of course, the fact that many clinically used anticonvulsants such as lamotrigine, phenytoin, and carbamazepine target Na_V channels [24].

Voltage-independent small-conductance Ca²⁺-activated K⁺ currents were first described in 1982 [28], and later found to be mediated by 3 closely related channels [29]: KCa2.1 (SK1 or KCNN1), KCa2.2 (SK2 or KCNN2), and KCa2.3 (SK3 or KCNN3). While KCa2.1 and KCa2.2 are particularly enriched in the cortex and the hippocampus, KCa2.3 is most prominet in subcortical areas like the striatum, thalamus, and monaminergic nuclei. KCa2 channels underlie the apamin-sensitive mAHP [30–32], and thus play an important role in controlling neuronal excitability and firing frequency. Pharmacological modulation of KCa channels therefore offers the opportunity to affect significantly neuronal activity. While KCa2 channel blockers like the bee venom toxin apamin increase firing rates, induce high frequency bursts in neurons that normally exhibit regular tonic action potential firing [33], and can elicit seizures in rodents [34], KCa2 channel activators reduce neuronal firing rates and suppress epileptiform activity in cultured hippocampal neurons [23, 35, 36]. KCa2 channel activators have therefore been proposed for the treatment of CNS disorders that are characterized by hyperexcitability, such as epilepsy and ataxia [15]. While the data supporting the use of KCa2 activators in ataxia are relatively strong [37–41], this approach has yet to be validated as a viable epilepsy treatment strategy. However, several lines of evidence lend credence to the idea that KCa2 channels may play a role in regulating seizure discharges and could therefore be a target for epilepsy drug treatment. Genetically epilepsy prone rats exhibit reduced afterhyperpolarization (AHP) currents resulting in a marked reduction in spike frequency adaptation in CA3 hippocampal neurons [42], and have more recently been found to express lower levels of KCa2.1 and KCa2.3 but higher levels of KCa2.2 in inferior colliculus neurons [43], suggesting that KCa2 channel dysregulation may contribute to the seizure susceptibility of these animals. It has further been shown that rats rendered chronically epileptic as a result of pilocarpine-induced status epilepticus exhibit significantly reduced KCa2-mediated AHP currents in CA1 hippocampal neurons [44]. Additionally, there is limited pharmacological evidence supporting the view that KCa2 is a relevant AED target. Several KCa2 activators suppress 4-AP induced epileptiform activities in rat hippocampal neurons [36], while 1-ethyl-2-benzimidazolinone (EBIO) and SKA-31 have been found to be effective in the MES test in mice [13, 45].

The anticonvulsant profile of SKA-19 is similar to the profile of “classical” sodium channel blocking anticonvulsants. SKA-19 is very effective in the MES test in mice and rats, AGS-susceptible mice, and hippocampal kindled rats [1, 16]. However, presumably owing to the additional KCa2 channel activating effect, SKA-19 has a broader profile than Na_V-channel blocking anticonvulsants. SKA-19 also shows efficacy in the 6-Hz psychomotor seizure test at both 32 and 44 mA, suggesting that it might have some utility for therapy-resistant seizures [20]. In lamotrigine-resistant amygdala kindled rats, SKA-19 exhibited partial protection but could not be tested at higher doses without inducing sedation. Interestingly, SKA-19 is ineffective against clonic seizures induced by the GABA_A receptor antagonist PTZ, and, in this respect, is different from the clinically used K⁺ channel activator retigabine (ezogabine), which activates Kv7.2–Kv7.5 (KCNQ2–KCNQ5) channels and which shows efficacy against GABA_A receptor antagonist-induced seizures [24]. Out of the currently clinically used anticonvulsants, SKA-19 most closely matches the profiles of zonisamide and lacosamide, which both have a very similar anticonvulsant profile (i.e., activity in MES, 6-Hz, AGS, and kindled models but not against seizures induced by GABA_A antagonists) and which both inhibit Na_V channels, but are distinct from other Na_V blockers by exerting additional effects [24].

In the commonly used formalin pain model, SKA-19 shows a profile that resembles other Na_V channel blockers but is, again, a little broader. Phase I in the formalin model is thought to result from an activation of primary afferent neurons through direct stimulation of the transient receptor potential family channel TRPA1 by formalin and is effectively suppressed by local anesthetics such as lidocaine, selective Na_V1.7 blockers, and TRPA1 antagonists [22, 46]. The subsequent phase II, which is characterized by sensitization of CNS neurons in the dorsal horn, continuing afferent input and inflammation, responds to opioid analgesics, N-methyl-d-aspartate antagonists, gabapentin, and nonsteroidal anti-inflammatory drugs. SKA-19 is similar to TRPA1 antagonists like HC-030031 in that it effectively suppresses pain responses in phase I and phase IIA but then loses efficacy in phase IIB [22]. Whether this loss of efficacy is simply due to falling plasma levels as SKA-19 was administered 2 h prior to the intraplantar formalin injection, increasing unspecific effects of formalin or a lack of effect of SKA-19 on later stages of the pain process will require further investigation. However, taken together, the results obtained from the formalin and sciatic ligation models demonstrate that SKA-19 exerts not only anticonvulsant, but also analgesic effects.

Based on our findings with SKA-19 we propose that compounds combining KCa2 channel-activating and Na_v channel-blocking activity exert broad-spectrum anticonvulsant and analgesic effects. We would further like to point out that although SKA-19 exhibits a superior pharmacokinetic profile, especially better brain penetration, than its parent drug riluzole, riluzole essentially has the same pharmacological profile. Like SKA-19, riluzole is both a highly state- and use-dependent Na_V blocker and a KCa2 channel activator, and we would like to suggest that riluzole, which is typically viewed as an amyotrophic lateral sclerosis drug, but has recently been reported to improve the symptoms of cerebellar ataxia [47], should be reinvestigated as a possible anticonvulsant and analgesic.